{"dataset":{"name":"GLP-1 Sellers and Compounders: FDA Warning Letters","description":"Every row here is a warning letter the US Food and Drug Administration issued to a GLP-1 telehealth marketer, a compounding pharmacy, or an online seller of compounded semaglutide or tirzepatide, and every row carries a link straight to the letter as published on fda.gov. On top of the agency's own fields we record which molecules the letter implicates and, where the recipient is a company the register already covers, which seller it maps to. A letter discloses a regulatory action; it is not on its own a verdict on a seller.","url":"https://glpwatchdog.org/fda-warning-letters","creator":"GLP Watchdog","license":"https://creativecommons.org/licenses/by/4.0/","licenseName":"CC BY 4.0","dateModified":"2026-11-06","temporalCoverage":"2023-10-02/2026-10-30","rowCount":160,"csv":"https://glpwatchdog.org/api/datasets/fda-glp1-warning-letters.csv","catalog":"https://glpwatchdog.org/api/datasets/index.json","fields":[{"name":"company_name","description":"Recipient of the letter, as FDA names it."},{"name":"company_dba","description":"Alias the recipient trades under, where the letter records one; empty otherwise."},{"name":"letter_number","description":"FDA warning letter reference number."},{"name":"letter_date","description":"Date the letter was issued (YYYY-MM-DD)."},{"name":"posted_date","description":"Date FDA published the letter."},{"name":"issuing_office","description":"FDA office behind the letter. Every row currently in the set comes from the Center for Drug Evaluation and Research (CDER)."},{"name":"subject","description":"Letter subject line as published by FDA."},{"name":"matched_drugs","description":"GLP-1 molecules named in the violations, pipe-separated."},{"name":"matched_provider_slug","description":"Slug of the register entry the recipient maps to, matched on operating entity rather than name resemblance; empty where the recipient is not a seller we cover."},{"name":"status","description":"How we track the letter: active, closed-out, or withdrawn. Every row in the set is currently active, so treat the other two values as reserved rather than observed."},{"name":"fda_url","description":"Permanent URL of the letter on fda.gov."}]},"summary":{"asOf":"2026-11-06","rowCount":160,"license":"https://creativecommons.org/licenses/by/4.0/","licenseName":"CC BY 4.0","citation":"GLP Watchdog, \"GLP-1 Sellers and Compounders: FDA Warning Letters\", data as of 2026-11-06. https://glpwatchdog.org/fda-warning-letters","about":"160 FDA warning letters naming a GLP-1 drug, sent to telehealth sellers, compounders and ingredient suppliers. Each row links the letter on fda.gov. Data as of 2026-11-06.","letters_by_violation_kind":{"unclassified":1,"products-unapproved":37,"compounding-conditions":9,"misleading-claims":108,"cgmp":4,"other":1}},"rows":[{"company_name":"RonanRx, Inc.","company_dba":"RonanRx","letter_number":"737905","letter_date":"2026-10-30","posted_date":"2026-11-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026"},{"company_name":"Cheap Medicine Shop","company_dba":"","letter_number":"737810","letter_date":"2026-09-24","posted_date":"2026-10-06","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded (Internet Pharmacy)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026"},{"company_name":"Online Generic Medicine","company_dba":"","letter_number":"737806","letter_date":"2026-09-23","posted_date":"2026-10-06","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drug/Misbranded (Internet Pharmacy)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026"},{"company_name":"Empower Clinic Services, LLC","company_dba":"Empower Pharmacy","letter_number":"738238","letter_date":"2026-09-18","posted_date":"2026-09-22","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"empower-pharmacy","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026"},{"company_name":"Peak Performance Peptides","company_dba":"","letter_number":"735127","letter_date":"2026-08-24","posted_date":"2026-09-01","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"semaglutide|retatrutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"},{"company_name":"Royal Peptides LLC","company_dba":"","letter_number":"734884","letter_date":"2026-08-24","posted_date":"2026-09-01","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"semaglutide|tirzepatide|retatrutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026"},{"company_name":"NuScience Peptides LLC","company_dba":"","letter_number":"733652","letter_date":"2026-08-24","posted_date":"2026-09-01","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"semaglutide|retatrutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026"},{"company_name":"Peptide Partners LLC","company_dba":"","letter_number":"735063","letter_date":"2026-08-24","posted_date":"2026-09-01","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"semaglutide|tirzepatide|retatrutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"},{"company_name":"TXP Innovations LLC","company_dba":"Tex Peptides","letter_number":"735067","letter_date":"2026-08-24","posted_date":"2026-09-01","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"semaglutide|tirzepatide|retatrutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026"},{"company_name":"Maximus Health, Inc.","company_dba":"Maximus","letter_number":"730095","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"maximus-tribe","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026"},{"company_name":"Trinity HealthCare Supply, LLC","company_dba":"altRx","letter_number":"728236","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"altrx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trinity-healthcare-supply-llc-dba-altrx-728236-06082026"},{"company_name":"Glow Medispa, LLC","company_dba":"Mint Med","letter_number":"730390","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"mint-med","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glow-medispa-llc-dba-mint-med-730390-06082026"},{"company_name":"Ezra Holdco LLC","company_dba":"Ezra","letter_number":"730995","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ezra-holdco-llc-dba-ezra-730995-06082026"},{"company_name":"Public Health Solution LLC","company_dba":"DrMedHealth","letter_number":"728278","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"drmedhealth","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/public-health-solution-llc-dba-drmedhealth-728278-06082026"},{"company_name":"D&H Medical Services","company_dba":"","letter_number":"728238","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dh-medical-services-728238-06082026"},{"company_name":"Amie Health, Inc.","company_dba":"Amie","letter_number":"728276","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amie-health-inc-dba-amie-728276-06082026"},{"company_name":"Altru Telehealth, LLC","company_dba":"Altru Telehealth","letter_number":"728274","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/altru-telehealth-llc-dba-altru-telehealth-728274-06082026"},{"company_name":"Eden Health International Inc.","company_dba":"Eden","letter_number":"728279","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"eden","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eden-health-international-inc-dba-eden-728279-06082026"},{"company_name":"NativeMed LLC","company_dba":"NativeMed","letter_number":"728287","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"nativemed","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nativemed-llc-dba-nativemed-728287-06082026"},{"company_name":"FitRX, LLC","company_dba":"AM RX","letter_number":"728275","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"amrx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-am-rx-728275-06082026"},{"company_name":"Momentum Health 360","company_dba":"Momentum Health","letter_number":"728286","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026"},{"company_name":"Medica Weight Loss","company_dba":"","letter_number":"728284","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medica-weight-loss-728284-06082026"},{"company_name":"Clover Meds LLC","company_dba":"Clover Meds","letter_number":"728234","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"clover-meds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clover-meds-llc-dba-clover-meds-728234-06082026"},{"company_name":"Nexlife Inc.","company_dba":"Nexlife","letter_number":"730096","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"nexlife","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexlife-inc-dba-nexlife-730096-06082026"},{"company_name":"Joi and Blokes","company_dba":"Joi + Blokes","letter_number":"728283","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"joi-and-blokes","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/joi-and-blokes-dba-joi-blokes-728283-06082026"},{"company_name":"VivioMD Group LLC","company_dba":"VivioMD","letter_number":"728295","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"viviomd","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viviomd-group-llc-dba-viviomd-728295-06082026"},{"company_name":"Nexus Health Solutions LLC","company_dba":"Harper Meds","letter_number":"728281","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"harper-meds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexus-health-solutions-llc-dba-harper-meds-728281-06082026"},{"company_name":"Nova Vascular LLC","company_dba":"NOVARX","letter_number":"728290","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nova-vascular-llc-dba-novarx-728290-06082026"},{"company_name":"Ready Med","company_dba":"","letter_number":"730317","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026"},{"company_name":"OrderlyMeds LLC","company_dba":"OrderlyMeds","letter_number":"728291","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"orderlymeds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orderlymeds-llc-dba-orderlymeds-728291-06082026"},{"company_name":"HydraMed IV LLC","company_dba":"HydraMed","letter_number":"728282","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"hydramed","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hydramed-iv-llc-dba-hydramed-728282-06082026"},{"company_name":"FITISH","company_dba":"","letter_number":"728280","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"fitish","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026"},{"company_name":"Thrivelab Co.","company_dba":"Thrivelab","letter_number":"728294","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"thrivelab","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrivelab-co-dba-thrivelab-728294-06082026"},{"company_name":"Roen Health, Inc.","company_dba":"RoenRx","letter_number":"728293","letter_date":"2026-06-08","posted_date":"2026-06-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"roen-rx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026"},{"company_name":"Harbin Jixianglong Biotech Co., Ltd.","company_dba":"","letter_number":"723330","letter_date":"2026-05-01","posted_date":"2026-05-19","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"CGMP/API/Adulterated and Misbranded Drugs","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026"},{"company_name":"New Life Pharma LLC","company_dba":"","letter_number":"725661","letter_date":"2026-04-14","posted_date":"2026-04-21","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"CGMP/Adulterated and Unapproved New Drug/Misbranded","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-life-pharma-llc-725661-04142026"},{"company_name":"ProRx LLC","company_dba":"","letter_number":"723704","letter_date":"2026-04-07","posted_date":"2026-05-12","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026"},{"company_name":"Prime Sciences","company_dba":"","letter_number":"721805","letter_date":"2026-03-31","posted_date":"2026-04-07","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs Sold Over the Internet","matched_drugs":"retatrutide|semaglutide|tirzepatide|cagrilintide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026"},{"company_name":"Mile High Compounds LLC","company_dba":"","letter_number":"721600","letter_date":"2026-03-31","posted_date":"2026-04-07","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs Sold Over the Internet","matched_drugs":"retatrutide|semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026"},{"company_name":"Lovega LLC","company_dba":"Pink Pony Peptides","letter_number":"721088","letter_date":"2026-03-31","posted_date":"2026-04-07","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs Sold Over the Internet","matched_drugs":"retatrutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovega-llc-dba-pink-pony-peptides-721088-03312026"},{"company_name":"Gram Peptides","company_dba":"","letter_number":"721806","letter_date":"2026-03-31","posted_date":"2026-04-07","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs Sold Over the Internet","matched_drugs":"retatrutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"},{"company_name":"PekCura Labs","company_dba":"","letter_number":"721709","letter_date":"2026-03-31","posted_date":"2026-04-07","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs Sold Over the Internet","matched_drugs":"cagrilintide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026"},{"company_name":"Novo Nordisk Inc.","company_dba":"","letter_number":"717576","letter_date":"2026-03-05","posted_date":"2026-03-10","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Postmarketing Adverse Drug Experience Reporting Requirements","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-717576-03052026"},{"company_name":"Zeuss LLC","company_dba":"Zeuss","letter_number":"717985","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"tirzepatide","matched_provider_slug":"zeuss","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zeuss-llc-dba-zeuss-717985-02202026"},{"company_name":"Weightless Medical LLC","company_dba":"WeightCare","letter_number":"721478","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"weightcare","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/weightless-medical-llc-dba-weightcare-721478-02202026"},{"company_name":"Viv Health, Inc.","company_dba":"VIV RX","letter_number":"721818","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viv-health-inc-dba-viv-rx-721818-02202026"},{"company_name":"Strut Health, LLC","company_dba":"Strut","letter_number":"721448","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"strut-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strut-health-llc-dba-strut-721448-02202026"},{"company_name":"Refills Health, LLC","company_dba":"Refills Health","letter_number":"721475","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide","matched_provider_slug":"refills","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/refills-health-llc-dba-refills-health-721475-02202026"},{"company_name":"Premium Health Management Inc.","company_dba":"Premium Health","letter_number":"721474","letter_date":"2026-02-20","posted_date":"2026-03-05","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"premium-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premium-health-management-inc-dba-premium-health-721474-02202026"},{"company_name":"PharmaZee","company_dba":"","letter_number":"721473","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmazee-721473-02202026"},{"company_name":"Peaks Curative, LLC","company_dba":"Peaks","letter_number":"721817","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peaks-curative-llc-dba-peaks-721817-02202026"},{"company_name":"NewSelf Limited","company_dba":"NewSelf","letter_number":"721472","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"newself","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newself-limited-dba-newself-721472-02202026"},{"company_name":"Newman Clinic, PLLC","company_dba":"Newman Clinic","letter_number":"721470","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newman-clinic-pllc-dba-newman-clinic-721470-02202026"},{"company_name":"MEDVi, LLC","company_dba":"MEDVi","letter_number":"721455","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"medvi","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026"},{"company_name":"MaxLife Technologies Inc.","company_dba":"Maxlife","letter_number":"721453","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"maxlife","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maxlife-technologies-inc-dba-maxlife-721453-02202026"},{"company_name":"Levity Inc.","company_dba":"Levity","letter_number":"717990","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide","matched_provider_slug":"levity","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"},{"company_name":"Lean Rx, Inc.","company_dba":"SkinnyRx","letter_number":"717989","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"skinnyrx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026"},{"company_name":"Kin Meds","company_dba":"","letter_number":"721450","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"kin-meds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026"},{"company_name":"Kare Solutions, LLC","company_dba":"Zappy","letter_number":"717991","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"zappy-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kare-solutions-llc-dba-zappy-717991-02202026"},{"company_name":"Join Josie","company_dba":"","letter_number":"717986","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"josie","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/join-josie-717986-02202026"},{"company_name":"Ivim Services LLC","company_dba":"Ivim","letter_number":"721816","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"ivim-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivim-services-llc-dba-ivim-721816-02202026"},{"company_name":"Good Girl LLC","company_dba":"GoodGirlRX","letter_number":"721449","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"good-girl-rx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/good-girl-llc-dba-goodgirlrx-721449-02202026"},{"company_name":"Genesis Health International Inc.","company_dba":"Genesis","letter_number":"721451","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"genesis","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genesis-health-international-inc-dba-genesis-721451-02202026"},{"company_name":"FitRX, LLC","company_dba":"FitRx","letter_number":"717987","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"fitrx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-fitrx-717987-02202026"},{"company_name":"Dripgym Mobile Parent, LLC","company_dba":"Amp Health","letter_number":"717992","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"amp-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dripgym-mobile-parent-llc-dba-amp-health-717992-02202026"},{"company_name":"Deluxe IV Aesthetics PLLC","company_dba":"Deluxe IV and Aesthetics","letter_number":"721447","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/deluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026"},{"company_name":"BluefitMD","company_dba":"","letter_number":"721446","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bluefitmd-721446-02202026"},{"company_name":"Bliv Wellness LLC","company_dba":"Bliv","letter_number":"721479","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"bliv","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bliv-wellness-llc-dba-bliv-721479-02202026"},{"company_name":"Better Health Labs, Inc.","company_dba":"Measured","letter_number":"721454","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"measured","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/better-health-labs-inc-dba-measured-721454-02202026"},{"company_name":"Belle Health LLC","company_dba":"Belle","letter_number":"721795","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"belle-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/belle-health-llc-dba-belle-721795-02202026"},{"company_name":"Aspen Aesthetics","company_dba":"Fifty 410","letter_number":"721481","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"fifty-410","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-aesthetics-dba-fifty-410-721481-02202026"},{"company_name":"Alan Health Technologies Inc.","company_dba":"Alan","letter_number":"721814","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"alan-meds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alan-health-technologies-inc-dba-alan-721814-02202026"},{"company_name":"24HrDoc, Inc.","company_dba":"24HrDoc","letter_number":"717984","letter_date":"2026-02-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"24hrdoc","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/24hrdoc-inc-dba-24hrdoc-717984-02202026"},{"company_name":"Thrive Health and Wellness, LLC","company_dba":"Thrive Health Solutions","letter_number":"714891","letter_date":"2026-02-09","posted_date":"2026-04-21","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026"},{"company_name":"GenoGenix LLC","company_dba":"","letter_number":"718739","letter_date":"2026-01-20","posted_date":"2026-03-03","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"retatrutide|semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026"},{"company_name":"Boothwyn Pharmacy, LLC","company_dba":"","letter_number":"717525","letter_date":"2026-01-16","posted_date":"2026-02-10","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boothwyn-pharmacy-llc-717525-01162026"},{"company_name":"Darmerica, LLC","company_dba":"","letter_number":"716152","letter_date":"2025-12-08","posted_date":"2025-12-23","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded","matched_drugs":"retatrutide|cagrilintide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025"},{"company_name":"Apothecary Pharma, LLC","company_dba":"","letter_number":"717972","letter_date":"2025-12-01","posted_date":"2026-03-17","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apothecary-pharma-llc-717972-12012025"},{"company_name":"PQ Pharmacy, LLC","company_dba":"","letter_number":"715795","letter_date":"2025-10-10","posted_date":"2025-12-02","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pq-pharmacy-llc-715795-10102025"},{"company_name":"Chengdu Brilliant Biopharmaceutical Co., Ltd.","company_dba":"","letter_number":"711330","letter_date":"2025-09-11","posted_date":"2025-09-23","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"CGMP/Finished Pharmaceuticals/Adulterated","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chengdu-brilliant-biopharmaceutical-co-ltd-711330-09112025"},{"company_name":"Motionpharmacycom","company_dba":"","letter_number":"715595","letter_date":"2025-09-10","posted_date":"2025-09-10","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/motionpharmacycom-715595-09102025"},{"company_name":"Try Nova","company_dba":"","letter_number":"716695","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"nova-md","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/try-nova-716695-09092025"},{"company_name":"SemaBio","company_dba":"","letter_number":"715866","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/semabio-715866-09092025"},{"company_name":"Novo Nordisk Inc.","company_dba":"","letter_number":"716495","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025"},{"company_name":"Master Pharmaceuticals Group","company_dba":"","letter_number":"715800","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/master-pharmaceuticals-group-715800-09092025"},{"company_name":"Lyfe Rx","company_dba":"","letter_number":null,"letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"lyfe-rx","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lyfe-rx-09092025"},{"company_name":"Las Villas Health Care LLC","company_dba":"Villas Health","letter_number":"716504","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/las-villas-health-care-llc-dba-villas-health-716504-09092025"},{"company_name":"iVisitDoc, Inc.","company_dba":"iVisitDoc","letter_number":"716826","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivisitdoc-inc-dba-ivisitdoc-716826-09092025"},{"company_name":"Invigorate Med Spa","company_dba":"","letter_number":"715872","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/invigorate-med-spa-715872-09092025"},{"company_name":"Healthy Living Clinic","company_dba":"","letter_number":null,"letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-living-clinic-09092025"},{"company_name":"Hcg Institute","company_dba":"","letter_number":"716512","letter_date":"2025-09-09","posted_date":"2025-09-09","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hcg-institute-716512-09092025"},{"company_name":"FWD Care, Inc.","company_dba":"FWD","letter_number":"716696","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"fwd-care","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fwd-care-inc-dba-fwd-716696-09092025"},{"company_name":"FitRX, LLC","company_dba":"Zealthy","letter_number":"716501","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"zealthy","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-zealthy-716501-09092025"},{"company_name":"EvoLife Wellness","company_dba":"","letter_number":"715507","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evolife-wellness-715507-09092025"},{"company_name":"Elite Health Center","company_dba":"","letter_number":"715869","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elite-health-center-715869-09092025"},{"company_name":"Eli Lilly and Company","company_dba":"","letter_number":"716485","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716485-09092025"},{"company_name":"Eli Lilly and Company","company_dba":"","letter_number":"716475","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716475-09092025"},{"company_name":"Eli Lilly and Company","company_dba":"","letter_number":"716462","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716462-09092025"},{"company_name":"eDrugstore","company_dba":"","letter_number":"716505","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/edrugstore-716505-09092025"},{"company_name":"Cosmo Medical Spa","company_dba":"Cosmo Med Spa","letter_number":"715873","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025"},{"company_name":"Amazing Meds","company_dba":"","letter_number":"715506","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet","matched_drugs":"retatrutide|semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazing-meds-715506-09092025"},{"company_name":"Body Good Studio","company_dba":"","letter_number":"716460","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/body-good-studio-716460-09092025"},{"company_name":"Canada Med Stop","company_dba":"","letter_number":"716517","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/canada-med-stop-716517-09092025"},{"company_name":"All American Wellness","company_dba":"","letter_number":"715991","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/all-american-wellness-715991-09092025"},{"company_name":"Intimate Rose","company_dba":"","letter_number":"716458","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"intimate-rose","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intimate-rose-716458-09092025"},{"company_name":"Dr. Gater’s Weight Loss & Wellness","company_dba":"","letter_number":"712866","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-gaters-weight-loss-wellness-712866-09092025"},{"company_name":"Remedy Meds","company_dba":"","letter_number":"716830","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"remedy-meds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/remedy-meds-716830-09092025"},{"company_name":"EA WORKS Limited Liability Company","company_dba":"Trust Labs","letter_number":"715798","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"retatrutide|semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ea-works-limited-liability-company-dba-trust-labs-715798-09092025"},{"company_name":"Fancy Meds, LLC","company_dba":"Fancy Meds","letter_number":"716487","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"fancymeds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fancy-meds-llc-dba-fancy-meds-716487-09092025"},{"company_name":"MyStart Health LLC","company_dba":"","letter_number":"714755","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"mystart-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/matthew-stern-ceo-mystart-health-llc-714755-09092025"},{"company_name":"Curex","company_dba":"","letter_number":"716821","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"curex","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curex-716821-09092025"},{"company_name":"Healthon Inc.","company_dba":"Healthon","letter_number":"719809","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"healthon","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthon-inc-dba-healthon-719809-09092025"},{"company_name":"JulyMD","company_dba":"","letter_number":"716828","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/julymd-716828-09092025"},{"company_name":"Slendid","company_dba":"","letter_number":"716700","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/slendid-716700-09092025"},{"company_name":"Sprout Health Partners LLC","company_dba":"Sprout Health","letter_number":"715879","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"sprout-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sprout-health-partners-llc-dba-sprout-health-715879-09092025"},{"company_name":"TRYM Health, Inc.","company_dba":"TRYM Health","letter_number":"716699","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"trym-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trym-health-inc-dba-trym-health-716699-09092025"},{"company_name":"HealBerry","company_dba":"","letter_number":"719809","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healberry-719809-09092025"},{"company_name":"Reset IV, LLC","company_dba":"Reset IV","letter_number":"716488","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reset-iv-llc-dba-reset-iv-716488-09092025"},{"company_name":"Expert Aesthetics","company_dba":"","letter_number":"715796","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/expert-aesthetics-715796-09092025"},{"company_name":"Lovely Meds, Inc.","company_dba":"Lovely Meds","letter_number":"716829","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"lovelymeds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovely-meds-inc-dba-lovely-meds-716829-09092025"},{"company_name":"Vitals RX","company_dba":"","letter_number":"715868","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vitals-rx-715868-09092025"},{"company_name":"ybycmeds","company_dba":"","letter_number":"715878","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ybycmeds-715878-09092025"},{"company_name":"GenLabMeds","company_dba":"","letter_number":"713650","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"retatrutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"},{"company_name":"Lean Dreams LLC","company_dba":"LeanDreams","letter_number":"716697","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-dreams-llc-dba-leandreams-716697-09092025"},{"company_name":"Tuyo Health, Inc.","company_dba":"Tuyo Health","letter_number":"716502","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"tuyo-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tuyo-health-inc-dba-tuyo-health-716502-09092025"},{"company_name":"Get.Fit.Medical, LLC","company_dba":"Get.Fit.Medical","letter_number":"715801","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/getfitmedical-llc-dba-getfitmedical-715801-09092025"},{"company_name":"inspire.clinic","company_dba":"","letter_number":"715799","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inspireclinic-715799-09092025"},{"company_name":"Bioverse, Inc.","company_dba":"Bioverse","letter_number":"716508","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"bioverse","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bioverse-inc-dba-bioverse-716508-09092025"},{"company_name":"SimpleRx","company_dba":"","letter_number":"715874","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/simplerx-715874-09092025"},{"company_name":"Elevate Your Wellness LLC,","company_dba":"Elevated","letter_number":"719811","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"elevated-health","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elevate-your-wellness-llc-dba-elevated-719811-09092025"},{"company_name":"Nuvo Life Health Inc.","company_dba":"Nuvo Life Health","letter_number":"715794","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuvo-life-health-inc-dba-nuvo-life-health-715794-09092025"},{"company_name":"directmeds.com, Inc.","company_dba":"DirectMeds","letter_number":"716822","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"direct-meds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/directmedscom-inc-dba-directmeds-716822-09092025"},{"company_name":"Lumimeds","company_dba":"","letter_number":"716510","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"lumimeds","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lumimeds-716510-09092025"},{"company_name":"GLP-1 Solution","company_dba":"","letter_number":"715883","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"retatrutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025"},{"company_name":"Healthy Male","company_dba":"","letter_number":"716506","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-male-716506-09092025"},{"company_name":"Hims & Hers Health, Inc.","company_dba":"Hims","letter_number":"716567","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"hims","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025"},{"company_name":"MedClub by Dr. Jenn","company_dba":"","letter_number":"712126","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"retatrutide|semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025"},{"company_name":"Mane & Steel, LLC.","company_dba":"Mane & Steel","letter_number":"716455","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mane-steel-llc-dba-mane-steel-716455-09092025"},{"company_name":"ASN-LABS","company_dba":"","letter_number":"716459","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"retatrutide|semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025"},{"company_name":"Hims & Hers Health, Inc.","company_dba":"Hers","letter_number":"716825","letter_date":"2025-09-09","posted_date":"2025-09-16","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","matched_drugs":"semaglutide","matched_provider_slug":"hers","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-716825-09092025"},{"company_name":"cheaptrustedpharmacy.com","company_dba":"","letter_number":"705501","letter_date":"2025-07-29","posted_date":"2025-09-23","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheaptrustedpharmacycom-705501-07292025"},{"company_name":"Wwwbuynetmedscom","company_dba":"","letter_number":"706335","letter_date":"2025-06-12","posted_date":"2025-06-12","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwbuynetmedscom-706335-06122025"},{"company_name":"Wwwpeacefulmedscom","company_dba":"","letter_number":"703470","letter_date":"2025-05-05","posted_date":"2025-05-05","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwpeacefulmedscom-703470-05052025"},{"company_name":"Www24Hreupbiz","company_dba":"","letter_number":"700358","letter_date":"2025-04-23","posted_date":"2025-04-23","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/www24hreupbiz-700358-04232025"},{"company_name":"Tailstorm Health Inc.","company_dba":"Medivant Health","letter_number":"703497","letter_date":"2025-04-08","posted_date":"2025-05-13","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailstorm-health-inc-dba-medivant-health-703497-04082025"},{"company_name":"ProRx, LLC","company_dba":"","letter_number":"696742","letter_date":"2025-03-04","posted_date":"2025-03-04","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounding Pharmacy/Adulterated Drug Products","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-696742-03042025"},{"company_name":"Usapeptidecom","company_dba":"","letter_number":"696885","letter_date":"2025-02-26","posted_date":"2025-02-26","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025"},{"company_name":"Wwwweightcrunchshopcom","company_dba":"","letter_number":"695815","letter_date":"2025-01-13","posted_date":"2025-01-13","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwweightcrunchshopcom-695815-01132025"},{"company_name":"Xcel Research LLC","company_dba":"","letter_number":"694608","letter_date":"2024-12-10","posted_date":"2024-12-17","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"retatrutide|semaglutide|cagrilintide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024"},{"company_name":"Swisschems","company_dba":"","letter_number":"695663","letter_date":"2024-12-10","posted_date":"2024-12-17","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"retatrutide|semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024"},{"company_name":"Summit Research Peptides","company_dba":"","letter_number":"695607","letter_date":"2024-12-10","posted_date":"2024-12-17","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"retatrutide|semaglutide|tirzepatide|cagrilintide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024"},{"company_name":"Prime Vitality, Inc.","company_dba":"Prime Peptides","letter_number":"695156","letter_date":"2024-12-10","posted_date":"2024-12-17","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"retatrutide|semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024"},{"company_name":"Nomidabiz","company_dba":"","letter_number":"687590","letter_date":"2024-09-12","posted_date":"2024-09-12","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nomidabiz-687590-09122024"},{"company_name":"AnuMed International, LLC","company_dba":"","letter_number":"674310","letter_date":"2024-08-20","posted_date":"2024-08-27","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anumed-international-llc-674310-08202024"},{"company_name":"Ozempencom","company_dba":"","letter_number":"684435","letter_date":"2024-06-24","posted_date":"2024-06-24","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ozempencom-684435-06242024"},{"company_name":"Wwwdashpctcom","company_dba":"","letter_number":"679727","letter_date":"2024-04-24","posted_date":"2024-04-24","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwdashpctcom-679727-04242024"},{"company_name":"US Chem Labs","company_dba":"","letter_number":"669074","letter_date":"2024-02-07","posted_date":"2024-02-13","issuing_office":"Center for Drug Evaluation and Research | CDER","subject":"CGMP/Finished Pharmaceuticals/Adulterated","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024"},{"company_name":"Synthetix Inc.","company_dba":"Helix Chemical Supply","letter_number":"668918","letter_date":"2024-02-07","posted_date":"2024-02-13","issuing_office":"Center for Drug Evaluation and Research | CDER","subject":"Unapproved New Drugs/Misbranded","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synthetix-inc-dba-helix-chemical-supply-668918-02072024"},{"company_name":"Wwwsemaspacecom","company_dba":"","letter_number":"665848","letter_date":"2023-10-02","posted_date":"2023-10-02","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwsemaspacecom-665848-10022023"},{"company_name":"Wwwgorillahealingcom","company_dba":"","letter_number":"664245","letter_date":"2023-10-02","posted_date":"2023-10-02","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"Compounded GLP-1 marketing and labeling concerns","matched_drugs":"semaglutide|tirzepatide","matched_provider_slug":"","status":"active","fda_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwgorillahealingcom-664245-10022023"}]}